je.st
news
Premarket Biotech Digest: Anavex's Results, Gilead's HCV Sales, Sanofi's Strategic Roadmap
2015-11-09 20:25:41| Biotech - Topix.net
Click this link to find out how much you can save.) Anavex is down 8% premarket after a large drop on Friday, just before the Nov 7 results from 32 patients in its phase 2a trial part A. I plan to do a thorough study of this tomorrow, but meanwhile, here are a few quick thoughts for those who are undecided about whether to sell or hold. . First, if you want to follow someone's advice, take it in its entirety, don't do it piecemeal.
Tags: results
sales
strategic
digest
Category:Biotechnology and Pharmaceuticals